Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine intranasal - Seelos Therapeutics

Drug Profile

Ketamine intranasal - Seelos Therapeutics

Alternative Names: Ereska; IN Ketamine; Intranasal ketamine; Intranasal racemic ketamine; PMI-100; PMI-150; SLS-002; TUR-002

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Javelin Pharmaceuticals
  • Developer Seelos Therapeutics
  • Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Neuroprotectants; Obesity therapies; Small molecules
  • Mechanism of Action AMPA receptor agonists; Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Suicidal ideation
  • Discontinued Acute pain; Cancer pain

Most Recent Events

  • 22 Jan 2024 Seelos Therapeutics announces the receipt of minutes from its end of phase II meeting with the US FDA highlighting modification of primary and secondary endpoints for phase III development
  • 22 Jan 2024 Seelos Therapeutics plans a phase III trial for Suicidal ideation in patients with Major depressive disorder in USA
  • 27 Nov 2023 Seelos Therapeutics plans phase II trial for Ketamine intranasal in post-traumatic stress disorder (PTSD) (NCT05422612).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top